Lung Diseases Clinical Trial
Official title:
Risk Factors in Bronchopulmonary Dysplasia (Newborn Lung Project)
To investigate risk factors in bronchopulmonary dysplasia (BPD) and to elucidate the relationship between BPD, acute lung disease severity, respiration-related variables, water balance, nutrition, familial predisposition, and environmental, pregnancy, and delivery parameters.
BACKGROUND:
Despite many improvements in neonatal intensive care during the decade from 1977 to 1987,
infant respiratory distress syndrome remained a major public health problem. Increasing
survival among premature infants led to the emergence of BPD as the major chronic respiratory
disorder of infancy. The vast majority of BPD occurs in very low birth weight infants
weighing less than 1,500 grams.
Although the incidence of low birth weight births declined from 1977 to 1987, the rate of
very low birth weight births remained unchanged. These infants had a relative risk of
neonatal death almost 200 times greater than full-term infants. Among survivors, eight
percent had evidence of chronic pulmonary disease at forty weeks of age. The Institute of
Medicine reported that very low birth weight infants who survived to one year of age were
hospitalized for an average of 57 days after birth versus 3.5 days for full-term infants. Up
to forty percent of these infants would be re-hospitalized almost two times for an average of
16 days versus 8.7 percent of normal birth weight infants for an average of 8 days.
DESIGN NARRATIVE:
The study had a nested case-control design. In the first year of the project, the diagnosis
of BPD was standardized and a scoring system developed for grading the severity of the
disease. Baseline data were collected on very low birth weight neonates admitted to seven
participating neonatal intensive care units. Maternal interviews were conducted for neonates
surviving seven days. The purpose of the interview was to collect information which m;ight be
related to a predisposition to BPD, respiratory distress syndrome, or prematurity. Specific
areas addressed included familial diseases in general and respiratory diseases in particular,
familial patterns of prematurity, pregnancy and birth history, circumstances surrounding
delivery, environmental exposures, health habits such as smoking, and socioeconomic
variables. Severity scoring and diagnosis of the infants were based on the hospital log and
routine x-rays. Final analysis compared infants with BPD to those without BPD, controlling
for confounders and placing special emphasis on interaction effects. Full-term neonates
served as controls.
The study was renewed in 1994 in order to re-contact at age 4-5, an existing cohort of 634
children with birth weight below 1501 grams. This cohort was unique in being representative
of all very low birth weight survivors in a geographic area, and in being born during a time
period of rapid advances in neonatal care (Aug 1, 1988-June 30, 1991). These children were
enrolled at admission to any of 6 neonatal intensive care units (NlCUs) in Wisconsin and
Iowa, and had extensive data already collected. The re-contact consisted of a telephone
interview with parents, including standardized functional assessment. Information on health
care and major diagnoses was also collected and verified by medical record abstracting.
Information on socioeconomic and insurance status was obtained. The study responded to a need
for global assessment of very low birth weight survivors, since most previous studies in the
United States focused on specific morbidity outcomes. Special features of already existing
data included scoring of respiratory distress syndrome and bronchopulmonary dysplasia
severity with new validated severity indices, baseline family health history information and
perinatal data. The cohort also spanned the time period from before general availability of
exogenous surfactant to its availability as an investigational new drug (8/1/89) and
availability for marketing (8/1/90). The study therefore provided an opportunity to
investigate the long term effectiveness of this new therapy in an unselected NlCU population.
The data were analyzed to describe the overall status of the cohort, to examine trends in
outcomes across the time period, to find predictors of outcome among the neonatal and
socioeconomic indicators and to investigate whether there was variability between centers.
The study was renewed in 1998 to continue follow-up of the cohort of 403 very low birth
weight neonatal care survivors, born during August 1988-June1991. The time period of birth
includes the approval dates for surfactant therapy. Hence, the first children to be treated
with surfactant in general neonatal intensive care units (NICU) are now entering school age,
providing an opportunity to evaluate school performance and to assess true chronicity of
respiratory limitations. A large NICU and follow-up data base on the cohort contains
extensive baseline assessment of respiratory disease, neonatal treatments and diagnoses, as
well as functional assessment, health status and health care utilization at ages 4-6. The
addition of data up to age 10 will confirm or dispute findings that functional outcome may be
lower among children born after surfactant was released for marketing, and that the
prevalence of long-term respiratory problems has remained the same. The new outcome data to
be collected include school performance from school records and parent and teacher
questionnaires, respiratory function by peak flow meters and respiratory symptoms and
medications by parent interviews and questionnaires.
The study was renewed in 2002 to continue research in the evolving risk factors and outcomes
of bronchopulmonary dysplasia (BPD) and other neonatal conditions of very low birth weight
(VLBW, < 1500g) infants and children. The renewal will comprehensively document the neonatal
and early childhood course and outcomes of all VLBW births in Wisconsin occurring during the
calendar years 2003 and 2004 (800-850 per year), using established methodology with added
risk factor information to examine currently proposed inflammatory hypotheses of BPD
etiology. The study will also implement and validate new diagnostic criteria for the severity
of BPD developed by a recent NIH workshop.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05563701 -
Evaluation of the LVivo Image Quality Scoring (IQS)
|
||
Completed |
NCT04908397 -
Carnitine Consumption and Augmentation in Pulmonary Arterial Hypertension
|
Phase 1 | |
Terminated |
NCT03309358 -
A Study of the Safety and Tolerability of Inhaled SNSP113 in Healthy Subjects and Subjects With Stable Cystic Fibrosis
|
Phase 1 | |
Completed |
NCT03682354 -
ESPB Versus INB With PCIA in Video-assisted Thoracic Surgery
|
N/A | |
Enrolling by invitation |
NCT03683186 -
A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension
|
Phase 3 | |
Completed |
NCT03626519 -
Effects of Menthol on Dyspnoea in COPD Patients
|
N/A | |
Recruiting |
NCT06004440 -
Real World Registry for Use of the Ion Endoluminal System
|
||
Completed |
NCT04874948 -
Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment
|
Phase 1 | |
Completed |
NCT02926768 -
Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT01443845 -
Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Dose Combinations of Long-acting β2-agonist (LABA) and Inhaled Corticosteroid (ICS)
|
Phase 4 | |
Completed |
NCT00281216 -
Innate and Adaptive Immunity in Individuals Experiencing Chronic Obstructive Pulmonary Disease Exacerbations
|
N/A | |
Terminated |
NCT00233207 -
IC14 Antibodies to Treat Individuals With Acute Lung Injury
|
Phase 2 | |
Completed |
NCT00269256 -
Stress, Environment, and Genetics in Urban Children With Asthma
|
N/A | |
Recruiting |
NCT00129350 -
Assessment of Heart and Heart-Lung Transplant Patient Outcomes Following Pulmonary Rehabilitation
|
Phase 1 | |
Active, not recruiting |
NCT00115297 -
Montelukast for Early Life Wheezing
|
Phase 2/Phase 3 | |
Completed |
NCT00094276 -
Intervention for Improving Asthma Care for Minority Children in Head Start
|
N/A | |
Completed |
NCT00091767 -
Genetic Studies in Difficult to Treat Asthma: TENOR
|
N/A | |
Completed |
NCT00069823 -
Study of Acid Reflux in Asthma
|
Phase 3 | |
Completed |
NCT00233168 -
Effectiveness of Public Health Model of Latent Tuberculosis Infection Control for High-Risk Adolescents
|
N/A | |
Completed |
NCT00083798 -
Family Linkage Study of Obstructive Sleep Apnea (OSA) in Iceland
|
N/A |